论文部分内容阅读
目的 探讨疟疾疗法治疗HIV感染的适应症。方法 按美国疾病控制中心（CDC）1993年修订的分类标准选择12例HIV-1感染者接受疟疾疗法治疗,其中5例诊断为CDCI类（CD4细胞计数≥500×106/L）,5例CDCⅡ类（CD4细胞计数200～499×106/L）,2例CDCⅢ类（CD4细胞计数<200×106/L）。用流式细胞仪法检测CD4细胞计数和百分率,bDNA法检测病毒载量。分别于治疗前第1次和第2次、第1次疟疾发热、第5次发热、第10次发热、终止疟疾后第10天、1个月、3个月、6个月、12个月、18个月和24个月采集血标本做检测。结果 病毒载量在所有 CDCI类和Ⅱ类患者于疟疾期均升高,在大部分I类和所有Ⅱ类患者于终止疟疾后回降到治疗前基线水平;2例CDCⅢ类患者经疟疾疗法治疗后病毒载量升高。治疗后3～24个月期间,I类患者CD4计数均降低,CD4百分率3例降低,2例升高;Ⅱ类患者CD4计数3例升高,2例维持稳定,CD4百分率4例升高,1例维持稳定;2例Ⅲ类患者CD4计数和百分率维持相对稳定不变。结论 疟疾疗法可能对CDCⅡ类HIV感染者有疗效。应该选CDCⅡ类患者做Ⅱ期（设对照组）临床试验,以进一步验证其疗效。
Objective To investigate the indications of malaria therapy for HIV infection. Methods According to the classification criteria revised by the American Disease Control Center (CDC) in 1993, 12 HIV-1 infected patients were selected for treatment of malaria. Among them, 5 cases were diagnosed as CDCI (CD4 cell count≥500 × 106 / L), 5 cases of CDCⅡ (CD4 cell count 200 ~ 499 × 106 / L) and 2 CDC class Ⅲ (CD4 cell count <200 × 106 / L). CD4 cell counts and percentages were determined by flow cytometry and viral load by bDNA. The first malaria fever, the fifth fever, the tenth fever, the tenth day, the first month, the third month, the sixth month, and the twelfth month after malaria were stopped before the first and second treatment respectively , 18 months and 24 months to collect blood samples for testing. Results The viral load was elevated during all malaria periods in all CDCI and II patients and returned to pretreatment baseline levels after most of the patients in category I and in all patients with category II malaria were discontinued. Two CDC patients were treated with malaria After the viral load increased. In the 3 to 24 months after treatment, the CD4 count in type I patients was decreased, the percentage of CD4 was decreased in 3 cases, and in 2 cases the level of CD4 counts in type 2 patients was increased in 3 cases, two cases remained stable, CD4 percentage increased in 4 cases, 1 patient remained stable; 2 patients with type III CD4 count and percentage remained relatively stable. Conclusion Malaria therapy may be effective in patients with CDC type II HIV infection. Should choose CDC Ⅱ type Ⅱ patients (control group) clinical trials to further verify its efficacy.